Archives: Agenda
Chair’s opening remarks
Chair’s opening remarks
END OF DAY 1 AND NETWORKING DRINKS
END OF DAY 1 AND NETWORKING DRINKS
Reaching underrepresented patients for trials in the current climate
- Why inclusive research is a business and clinical imperative
- How to continue the work in the current climate
- Increasing focus on US enrollment
- Five principles of data driven inclusive research
Embracing the unknown: Tips and tricks on how to grow your biotech
- Building a network to support your biotech through challenges
- Identifying weak points and understanding what you need to progress
- Balancing trust and control when navigating the unknown to curb risk and accelerate progression
CASE STUDY: What does it take to start up a biotech company from scratch?
- An overview of common challenges and how to overcome these
- Securing initial funding: navigating opportunities available to raise capital
- Overcoming early stage hurdles
- Building strategic partnerships to support your biotech
Making AI approachable
Speaker Hosted Round Tables
Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others. Each roundtable lasts for 30 minutes, delegates can select up to 2 roundtables.
| RT 1 | Revolutionizing healthcare: Incorporating new technologies to reduce the burden on sites, sponsors and CROs |
| RT 2 | Acknowledging the value that patients can bring to every stage of the drug development pathway |
| RT 3 | Navigating vendor selection: Reducing the noise of all the competing tools and services |
| RT 4 | Mitigating risk: how to strategically plan and curb risk as a small biotech |
| RT 5 | Balancing limited funds while ensuring patient centricity as a small biotech |
| RT 6 | Aligning ideas with investor expectations for effective pitching and successfully secure funding |